<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01168687</url>
  </required_header>
  <id_info>
    <org_study_id>H1815-29512-02</org_study_id>
    <secondary_id>W81XWH-05-1-0215</secondary_id>
    <nct_id>NCT01168687</nct_id>
  </id_info>
  <brief_title>Effects of Levetiracetam (Keppra) on Alcohol Consumption</brief_title>
  <official_title>Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goals of this study are to (1) expand knowledge about interactions of
      levetiracetam with alcohol by assessing the effects of levetiracetam compared to placebo in
      moderate and heavy social alcohol users and (2) to test the AccuswayTM platform as a tool to
      measure postural control (which has been used as a marker of intoxication) and the effects of
      levetiracetam on postural control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a 42-day, double-blind, placebo-controlled crossover study in light
      to moderate and heavy alcohol users who are social drinkers.

      The specific aims are to:

        1. Determine if levetiracetam alters daily alcohol consumption by comparing the mean drinks
           consumed per day during levetiracetam administration compared with the mean drinks per
           day consumed during placebo administration.

        2. Obtain blood that will be banked for future genetic analysis of polymorphisms in genes
           that may predict the level of response to alcohol or effects of levetiracetam on alcohol
           consumption.

        3. Test whether the AccuswayTM platform can detect changes in body sway in light to
           moderate or heavy social drinkers and in subjects taking levetiracetam versus placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard Alcoholic Drinks Per Treatment Period</measure>
    <time_frame>This will be assessed during a 42-day period.</time_frame>
    <description>The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Alcohol Abuse</condition>
  <condition>Drug Abuse</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twenty moderate to heavy social alcohol users (women 7-20 drinks/week --moderate 7-14 and heavy 15-20 and men 15-25 drinks/week --moderate 7-14 and heavy 15-25 drinks/week) will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twenty moderate to heavy social alcohol users as described above will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam (Keppra)</intervention_name>
    <description>Group A: Twenty moderate to heavy social alcohol users (women 7-20 drinks/week --moderate 7-14 and heavy 15-20 and men 15-25 drinks/week --moderate 7-14 and heavy 15-25 drinks/week) will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.
Group B: Twenty moderate to heavy social alcohol users as described above will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adults who are social drinkers 21 and 50 years of age.

          2. Moderate to heavy social drinkers (women=7-21 drinks/week, men=7-25 drinks/week).

          3. Body Mass Index (BMI)&gt;18 and &lt;30.

          4. If female, must be non-lactating, not pregnant, and using a reliable contraception
             method (i.e. abstinence, intrauterine device [IUD], hormonal birth control, or double
             barrier method [male condom, female condom, or diaphragm plus a spermicidal agent such
             as contraceptive foam, jelly or cream]).

          5. Able and willing to provide written informed consent.

          6. Able to understand and follow the instructions of the investigator, and understand all
             rating scales.

          7. Have a negative urine drug screen at all visits, with the exception of cannabinoids.

        Exclusion Criteria:

          1. Positive urine drug screen, except cannabinoids. Occasional cannabinoid use is
             allowed, however daily use, dependence, or if considered more than a casual user by
             study physician, subject will be excluded.

          2. Use of cocaine, amphetamines or other stimulants, hallucinogens, ecstasy or other
             psychoactive drugs, greater than 10 times in the last 24 months or at anytime in the
             past 60 days.

          3. Lifetime use of PCP or ketamine greater than 10 times, or at any time in the last 24
             months.

          4. History of abusing inhalants (such as glue, toluene or other volatile substances).

          5. Current or past dependence on, or addiction to any psychoactive drug (except nicotine
             or caffeine) including alcohol, as determined by the study physician's assessment.

          6. Current or prior enrollment in an alcohol or other drug treatment program, or current
             legal problems relating to alcohol or other drug use, including awaiting trial or
             supervision by a parole or probation officer.

          7. Binge drinking more than three times per week (binge defined as &gt;5 standard drinks in
             one session).

          8. Alcohol consumption &gt;21 drinks/week for women and &gt;25 drinks/week for men.

          9. Currently trying to quit alcohol and/or recreational drug use.

         10. Positive for lifetime abnormal opioid use or prescription drug abuse.

         11. Clinically significant medical or psychiatric illness (including anxiety or panic
             disorders) as determined by screening blood tests, medical history, and physical exam
             performed or reviewed by the study physician.

         12. Bilirubin more than 2 times the normal upper limit.

         13. AST (SGOT), ALT (SGPT), or alkaline phosphatase more than 2 times the normal upper
             limit.

         14. Body Mass Index &gt;30 or &lt;18

         15. Pregnancy or a woman of child bearing potential not currently using an adequate means
             of contraception.

         16. Currently taking any medication other than over-the-counter nonsteroidal
             anti-inflammatories, acetaminophen, inhaled asthma therapy, contraceptives, nicotine
             patches, and over-the-counter non-sedating antihistamines.NSAIDs, acetaminophen, or
             any other OTC (including herbal) medication (unless cleared by study physician).

         17. BAC level greater than 0.02% at the beginning of visits 1, 7, or 8 (within margin of
             error for detection).

         18. Estimated creatinine clearance &lt; 50 ml/min.

         19. Chronic pain condition requiring regular physician visits and treatment under a
             physician's supervision.

         20. Neurological dysfunction or psychiatric disorder severe enough to interfere with
             assessment of outcome measures as defined above.

         21. Allergy to levetiracetam.

         22. Significant cardiac pathology or abnormal initial EKG with QT/QTc interval
             prolongation &gt; 480 m secs at baseline.

         23. Has received an investigational drug within 30 days prior to Study Visit 2 (after
             screening visit).

         24. Subjects who are unable to read or speak English.

         25. Those, in the opinion of the investigator, who are considered unable to adhere to
             scheduled appointments, unlikely to comply with the study protocol, or who are
             unsuitable for any other reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert O. Messing, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF; Department of Neurology; Ernest Gallo Clinic and Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer M. Mitchell, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF; Department of Neurology; Ernest Gallo Clinic and Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Oakland Research Institute- CRC</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Angehagen M, Margineanu DG, Ben-Menachem E, Rönnbäck L, Hansson E, Klitgaard H. Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons. Neuroreport. 2003 Mar 3;14(3):471-5.</citation>
    <PMID>12634506</PMID>
  </reference>
  <reference>
    <citation>Ardid D, Lamberty Y, Alloui A, Coudore-Civiale MA, Klitgaard H, Eschalier A. Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats. Eur J Pharmacol. 2003 Jul 18;473(1):27-33.</citation>
    <PMID>12877934</PMID>
  </reference>
  <reference>
    <citation>Brockmöller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther. 2005 Jun;77(6):529-41.</citation>
    <PMID>15961984</PMID>
  </reference>
  <reference>
    <citation>Cataldi M, Lariccia V, Secondo A, di Renzo G, Annunziato L. The antiepileptic drug levetiracetam decreases the inositol 1,4,5-trisphosphate-dependent [Ca2+]I increase induced by ATP and bradykinin in PC12 cells. J Pharmacol Exp Ther. 2005 May;313(2):720-30. Epub 2005 Jan 11.</citation>
    <PMID>15644427</PMID>
  </reference>
  <reference>
    <citation>Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006 Apr 28;312(5773):592-6. Epub 2006 Mar 16.</citation>
    <PMID>16543415</PMID>
  </reference>
  <reference>
    <citation>Grünewald R. Levetiracetam in the treatment of idiopathic generalized epilepsies. Epilepsia. 2005;46 Suppl 9:154-60.</citation>
    <PMID>16302890</PMID>
  </reference>
  <reference>
    <citation>Kim C, Jun K, Lee T, Kim SS, McEnery MW, Chin H, Kim HL, Park JM, Kim DK, Jung SJ, Kim J, Shin HS. Altered nociceptive response in mice deficient in the alpha(1B) subunit of the voltage-dependent calcium channel. Mol Cell Neurosci. 2001 Aug;18(2):235-45.</citation>
    <PMID>11520183</PMID>
  </reference>
  <reference>
    <citation>Krebs M, Leopold K, Richter C, Kienast T, Hinzpeter A, Heinz A, Schaefer M. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial. J Clin Psychopharmacol. 2006 Jun;26(3):347-9.</citation>
    <PMID>16702910</PMID>
  </reference>
  <reference>
    <citation>LaMotte RH, Lundberg LE, Torebjörk HE. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J Physiol. 1992 Mar;448:749-64.</citation>
    <PMID>1593488</PMID>
  </reference>
  <reference>
    <citation>Lipscomb TR, Carpenter JA, Nathan PE. Static ataxia: a predictor of alcoholism? Br J Addict Alcohol Other Drugs. 1979 Sep;74(3):289-94.</citation>
    <PMID>290377</PMID>
  </reference>
  <reference>
    <citation>Lipscomb TR, Nathan PE. Blood alcohol level discrimination. The effects of family history of alcoholism, drinking pattern, and tolerance. Arch Gen Psychiatry. 1980 May;37(5):571-6.</citation>
    <PMID>7377914</PMID>
  </reference>
  <reference>
    <citation>Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002 Jan;43(1):9-18.</citation>
    <PMID>11879381</PMID>
  </reference>
  <reference>
    <citation>Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6. Epub 2004 Jun 21.</citation>
    <PMID>15210974</PMID>
  </reference>
  <reference>
    <citation>Madeja M, Margineanu DG, Gorji A, Siep E, Boerrigter P, Klitgaard H, Speckmann EJ. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology. 2003 Oct;45(5):661-71.</citation>
    <PMID>12941379</PMID>
  </reference>
  <reference>
    <citation>Newton PM, Orr CJ, Wallace MJ, Kim C, Shin HS, Messing RO. Deletion of N-type calcium channels alters ethanol reward and reduces ethanol consumption in mice. J Neurosci. 2004 Nov 3;24(44):9862-9.</citation>
    <PMID>15525770</PMID>
  </reference>
  <reference>
    <citation>Pisani A, Bonsi P, Martella G, De Persis C, Costa C, Pisani F, Bernardi G, Calabresi P. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia. 2004 Jul;45(7):719-28.</citation>
    <PMID>15230693</PMID>
  </reference>
  <reference>
    <citation>Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, Leprince P, Moonen G, Selak I, Matagne A, Klitgaard H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002 Jul;136(5):659-72.</citation>
    <PMID>12086975</PMID>
  </reference>
  <reference>
    <citation>Rowbotham MC, Manville NS, Ren J. Pilot tolerability and effectiveness study of levetiracetam for postherpetic neuralgia. Neurology. 2003 Sep 23;61(6):866-7.</citation>
    <PMID>14504347</PMID>
  </reference>
  <reference>
    <citation>Schuckit MA, Smith TL, Kalmijn J. Findings across subgroups regarding the level of response to alcohol as a risk factor for alcohol use disorders: a college population of women and Latinos. Alcohol Clin Exp Res. 2004 Oct;28(10):1499-508.</citation>
    <PMID>15597082</PMID>
  </reference>
  <reference>
    <citation>Saegusa H, Kurihara T, Zong S, Kazuno A, Matsuda Y, Nonaka T, Han W, Toriyama H, Tanabe T. Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. EMBO J. 2001 May 15;20(10):2349-56.</citation>
    <PMID>11350923</PMID>
  </reference>
  <results_reference>
    <citation>Hatakeyama S, Wakamori M, Ino M, Miyamoto N, Takahashi E, Yoshinaga T, Sawada K, Imoto K, Tanaka I, Yoshizawa T, Nishizawa Y, Mori Y, Niidome T, Shoji S. Differential nociceptive responses in mice lacking the alpha(1B) subunit of N-type Ca(2+) channels. Neuroreport. 2001 Aug 8;12(11):2423-7.</citation>
    <PMID>11496122</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>July 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2010</study_first_posted>
  <results_first_submitted>January 16, 2013</results_first_submitted>
  <results_first_submitted_qc>February 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2013</results_first_posted>
  <last_update_submitted>February 22, 2013</last_update_submitted>
  <last_update_submitted_qc>February 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>keppra</keyword>
  <keyword>levetiracetam</keyword>
  <keyword>alcoholism</keyword>
  <keyword>genetics</keyword>
  <keyword>subjective report</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was conducted online (Craigslist) and from publicly posted flyers.</recruitment_details>
      <pre_assignment_details>Enrolled participants were excluded prior to medication dosing if blood testing revealed elevated liver enzymes or if urine testing indicated a pregnancy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A: Crossover Between Low Dose Keppra and Placebo</title>
          <description>Group A: Twenty moderate to heavy social alcohol users (women 7-20 drinks/week --moderate 7-14 and heavy 15-20 and men 15-25 drinks/week --moderate 7-14 and heavy 15-25 drinks/week) will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) or will receive a double dose of placebo x 7 days. Participants on active drug for the first 14 days then crossed over to placebo after a 10-14 day washout period. Similarly, participants on placebo for the first 14 days then crossed over to active drug after a 10-14 day washout period.</description>
        </group>
        <group group_id="P2">
          <title>Group B: Crossover Between High Dose Keppra and Placebo</title>
          <description>Group B: Twenty moderate to heavy social alcohol users (women 7-20 drinks/week --moderate 7-14 and heavy 15-20 and men 15-25 drinks/week --moderate 7-14 and heavy 15-25 drinks/week) will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days.
Participants on active drug for the first 14 days then crossed over to placebo after a 10-14 day washout period. Similarly, participants on placebo for the first 14 days then crossed over to active drug after a 10-14 day washout period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A: Crossover Between Low Dose Keppra and Placebo</title>
          <description>Group A: Twenty moderate to heavy social alcohol users (women 7-20 drinks/week --moderate 7-14 and heavy 15-20 and men 15-25 drinks/week --moderate 7-14 and heavy 15-25 drinks/week) will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) or will receive a double dose of placebo x 7 days. Participants on active drug for the first 14 days then crossed over to placebo after a 10-14 day washout period. Similarly, participants on placebo for the first 14 days then crossed over to active drug after a 10-14 day washout period.</description>
        </group>
        <group group_id="B2">
          <title>Group B: Crossover Between High Dose Keppra and Placebo</title>
          <description>Group B: Twenty moderate to heavy social alcohol users (women 7-20 drinks/week --moderate 7-14 and heavy 15-20 and men 15-25 drinks/week --moderate 7-14 and heavy 15-25 drinks/week) will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days.
Participants on active drug for the first 14 days then crossed over to placebo after a 10-14 day washout period. Similarly, participants on placebo for the first 14 days then crossed over to active drug after a 10-14 day washout period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Standard Alcoholic Drinks Per Treatment Period</title>
        <description>The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period.</description>
        <time_frame>This will be assessed during a 42-day period.</time_frame>
        <population>All study participants were used for data analysis. If there were no significant differences between the two doses of levetiracetam, data would be collapsed for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects (n = 46) Placebo</title>
            <description>23 moderate social drinkers. 23 heavy social drinkers.</description>
          </group>
          <group group_id="O2">
            <title>All Subjects (n = 46) Levetiracetam</title>
            <description>23 moderate social drinkers. 23 heavy social drinkers.</description>
          </group>
        </group_list>
        <measure>
          <title>Standard Alcoholic Drinks Per Treatment Period</title>
          <description>The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period.</description>
          <population>All study participants were used for data analysis. If there were no significant differences between the two doses of levetiracetam, data would be collapsed for analysis.</population>
          <units>number of drinks per treatment period</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" spread="2.8"/>
                    <measurement group_id="O2" value="45.4" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Subjects (n = 46) Placebo</title>
          <description>23 moderate social drinkers. 23 heavy social drinkers.</description>
        </group>
        <group group_id="E2">
          <title>All Subjects (n = 46) Levetiracetam</title>
          <description>23 moderate social drinkers. 23 heavy social drinkers.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Mitchell, Clinical Project Director</name_or_title>
      <organization>Ernest Gallo Clinic and Research Center, UCSF</organization>
      <phone>510-985-3100</phone>
      <email>jmitchell@gallo.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

